Circulating miRNA as a Biomarker in Oral Cancer Liquid Biopsy

Biomedicines. 2023 Mar 21;11(3):965. doi: 10.3390/biomedicines11030965.

Abstract

Oral cancer is currently challenging the healthcare system, with a high incidence among the population and a poor survival rate. One of the main focuses related to this malignancy is the urge to implement a viable approach for improving its early diagnosis. By introducing the use of liquid biopsy and the identification of potential biomarkers, aiming for a noninvasive approach, new advancements offer promising perspectives in the diagnosis of oral cancer. The present review discusses the potential of circulating miRNAs as oral cancer biomarkers identified in body fluids such as serum, plasma, and saliva samples of oral cancer patients. Existing results reveal an important implication of different miRNA expressions involved in the initiation, development, progression, and metastasis rate of oral malignancy. Liquid biomarkers can play a crucial role in the development of the concept of personalized medicine, providing a wide range of clinical applications and future targeted therapies.

Keywords: biomarker; early diagnosis; liquid biopsy; miRNA; noninvasive; oral cancer; saliva.

Publication types

  • Review

Grants and funding

This research received no external funding.